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Abstract
 
Background.
 
Vaccination rates are frequent-
ly considered a surrogate measure of protection. To pro-
vide more accurate estimates, serum levels of antibody
against tetanus were measured as part of the third Na-
tional Health and Nutrition Examination Survey (NHANES
III), which studied a representative sample of the civilian,
noninstitutionalized population of the United States. 
 
Methods.
 
We measured tetanus antitoxin using a sol-
id-phase enzyme immunoassay in serum samples from
10,618 persons six years of age and older who were ex-
amined during phase 1 of NHANES III in 1988 to 1991.
 
Results.
 
Overall, 69.7 percent of Americans six years
of age and older had protective levels of tetanus antibod-
ies (
 

 
0.15 IU per milliliter). The rate decreased from 87.7
percent among those 6 to 11 years of age to 27.8 percent
among those 70 years of age or older. Among children
6 to 16 years of age, 82.2 percent had protective levels
of tetanus antibodies, with little variation according to race
or ethnicity. More men than women were immune (79.0
percent vs. 62.4 percent). Mexican Americans had a sig-
nificantly lower rate of immunity (57.9 percent, P
 

 
0.05)
than either non-Hispanic whites (72.7 percent) or non-His-
panic blacks (68.1 percent). Those with a history of mili-
tary service, higher levels of education, or incomes above
the poverty level were more likely to have protective anti-
body levels. Although the prevalence of immunity declined
rapidly starting at the age of 40 years, most of the 107
cases of tetanus (with 20 deaths) reported in 1989 and
1990 occurred in persons 60 years of age or older.
 
Conclusions.
 
Despite the fact that effective vaccines
against tetanus have been available since the 1940s,
many Americans do not have immunity to tetanus, and
the rates are lowest among the elderly. There is an excel-
lent correlation between vaccination rates (96 percent)
and immunity (96 percent) among six-year-olds. Howev-
er, antibody levels decline over time, and one fifth of older
children (10 to 16 years of age) do not have protective an-
tibody levels. (N Engl J Med 1995;332:761-6.)
 
From the National Institute of Allergy and Infectious Diseases, National Insti-
tutes of Health, Bethesda, Md. (P.J.G.); National Center for Health Statistics,
Centers for Disease Control and Prevention, Hyattsville, Md. (G.M.M., T.M.E.-R.);
Maternal and Child Health Bureau, Health Resources Service Administration,
Rockville, Md. (M.K.); National Immunization Program, Centers for Disease
Control and Prevention, Atlanta (R.W.S.); and Department of Microbiology and
Immunology, Medical University of South Carolina, Charleston (G.V.). Address
reprint requests to Dr. Gergen at Solar, Rm. 4A29, 6003 Executive Blvd., MSC
7640, Bethesda, MD 20892-7640.
V
 
ACCINES are the most cost-effective public health
intervention.
 
1
 
 Children
 
2
 
 and the elderly
 
3,4
 
 are at
risk for insufficient immunization coverage. Much ef-
fort has been spent attempting to increase the coverage
among children. All 50 states have adopted laws requir-
ing children to be vaccinated before they are admitted
to school,
 
5,6
 
 and more than 96 percent of school-age
children now receive three or more vaccinations with
diphtheria and tetanus toxoids and pertussis vaccine
(DTP) at school entry.
 
2
 
 Vaccination rates have histori-
cally been lower in preschool children less than five
years of age (e.g., 70 to 80 percent),
 
7-9
 
 and the Child-
hood Immunization Initiative was created to increase
the level of vaccination coverage in this age group.
 
10
 
Vaccination rates are frequently considered a surro-
gate measure of protection. Serum levels of protective
antibody are a more objective measure. The first phase
of the third National Health and Nutrition Examina-
tion Survey (NHANES III), conducted from 1988 to
1991, offered the opportunity to examine the preva-
lence of protective levels of tetanus antibody in a rep-
resentative sample of the U.S. population and to iden-
tify subgroups susceptible to tetanus.
 
M
 
ETHODS
 
Survey Design and Data Collection
 
NHANES is a periodic national survey conducted by the National
Center for Health Statistics of the Centers for Disease Control and
Prevention (CDC). The survey is designed to provide national statis-
tics on the health and nutritional status of the civilian, noninstitution-
alized population through household interviews and standardized
physical examinations conducted in special mobile examination cen-
ters. With a sample of approximately 40,000 persons two months of
age or older, NHANES III has been divided into two three-year sur-
veys (phase 1 and phase 2) so that national estimates can be pro-
duced for each three-year period as well as for the total six-year
period. The survey was conducted from 1988 through 1994 in 89 ran-
domly selected locations throughout the United States. Data present-
ed here are from phase 1, which was conducted from October 1988
through October 1991.
NHANES III is based on a multistage probability-sample design.
Children under 5 years of age, persons 60 years of age and older,
Mexican Americans, and non-Hispanic blacks are included in the
survey at a higher rate than other persons. To produce national esti-
mates, the results for each person are adjusted or weighted to ac-
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count for the differential probabilities of selection and response.
 
11
 
 De-
tails of the sample design have been published elsewhere.
 
12
 
Laboratory Methods
 
The level of tetanus antitoxin was measured with a solid-phase en-
zyme immunoassay. Enzyme-immunoassay plates (Immulon I, Dyna-
tech, Chantilly, Va.) were coated with tetanus toxoid by incubating
them with tetanus toxoid (0.1 limit-of-flocculation unit per well; Wy-
eth-Ayerst Laboratories, Marietta, Ga.) diluted in 0.25 M sodium car-
bonate and bicarbonate buffer, pH 9.6. Serum samples were routinely
divided into two groups for testing. Serum samples from persons who
were 50 years of age or older were assayed at dilutions ranging from
1:10 to 1:200, because of the high frequency of low antibody concen-
trations in older persons. All other samples were studied in dilutions
ranging from 1:100 to 1:12,800. If the antibody concentration was too
low to be detected at these dilutions, the assay was repeated with dif-
ferent ranges of dilutions, starting at 1:10. The antibody concentra-
tion for each sample was calculated by averaging the values obtained
at three different dilutions. The methods have been described in de-
tail elsewhere.
 
13
 
The lower limit of detection for this assay is 0.001 IU per milliliter.
This is well below the level of antitoxin that is considered protective
on enzyme immunoassay — 20.16 IU per milliliter.
 
14
 
 For all analyses
in this report, protective levels of tetanus antitoxin are defined as
those exceeding 0.15 IU per milliliter. This value is considerably
higher than the level of 0.01 IU per milliliter that is used when anti-
body levels are determined by the neutralization assay in animals. Al-
though the enzyme immunoassay is specific, sensitive, and consider-
ably more accurate than the neutralization assay, the two assays yield
different results at antibody levels below 0.2 IU per milliliter, proba-
bly because the enzyme immunoassay quantitates antibodies with low
levels of neutralizing activity (e.g., IgM antibodies and low-affinity
antibodies in general). According to Simonsen et al.,
 
14
 
 antibody levels
above 0.15 IU per milliliter on enzyme immunoassay can be assumed
with reasonable confidence to be protective. Thus, we adopted this
value as our cutoff level.
The tetanus-antitoxin assay was performed on serum collected
from persons four years of age or older. Because of insufficient blood
collection, tetanus antibodies were measured in only 31 percent of
the children four and five years old. Consequently, all analyses are
restricted to persons six years of age or older.
 
Variables
 
Three mutually exclusive racial and ethnic groups were created on
the basis of the NHANES III sample design: non-Hispanic whites,
non-Hispanic blacks, and Mexican Americans. Persons not included
in one of these groups are included in estimates involving the total
population.
A participant’s age was defined as his or her age at the time of the
household interview. Educational level was determined on the basis
of the last completed year of schooling: elementary, post-elementary,
high school, or college. For children 6 to 16 years of age, the head of
household’s level of education was used in the analyses of immuniza-
tion status and educational level.
The poverty-index ratio was calculated by dividing the total family
income by the poverty threshold adjusted for family size for the year
of the interview, as determined by the Bureau of the Census.
 
15-17
 
 The
total family income included total family wages, salaries, Social Se-
curity benefits, retirement benefits, and any other earnings received
during the 12 months before the interview. A poverty-index ratio be-
low 1 was considered to indicate poverty.
County population size was used to determine whether an area was
urban or rural. Counties with populations of more than 1 million
were defined as urban.
Data on military service were based on respondents’ reports of
service in the armed forces of the United States. Only women with
no history of military service could be evaluated, because there were
too few female veterans in the survey.
 
Response Rates
 
Of the 13,714 persons six years of age or older who were inter-
viewed for the survey, 77.4 percent underwent a physical examination
and consented to phlebotomy, from which enough serum was ob-
tained to measure tetanus antitoxin. Response rates exceeded 81 per-
cent for all age groups except for children 6 to 11 years old (57.2 per-
cent) and persons 70 or more years old (72.4 percent). The response
rate varied little according to the place of birth and the poverty-index
ratio. Previous analyses of NHANES III data found that no apparent
bias was introduced by a nonresponse.
 
11,18
 
Tetanus Surveillance
 
A national surveillance of tetanus relies on the reporting of physi-
cian-diagnosed cases of tetanus to state and local health depart-
ments. State health departments report cases of tetanus on a weekly
basis to the CDC through the National Notifiable Diseases Surveil-
lance System. Supplemental clinical and epidemiologic information is
submitted by reporting states to the National Immunization Program
at the CDC.
 
19
 
 Data for 1989 and 1990 from the supplemental surveil-
lance system were analyzed to determine the incidence of tetanus ac-
cording to age in the United States.
 
Statistical Analysis
 
All prevalence estimates were weighted to account for oversam-
pling, lack of response to the household interview, and lack of phys-
ical examination. Population estimates were based on weights strati-
fied according to the Census Bureau’s Current Population Survey for
March 1990.
 
11,12
 
Standard errors were calculated with SUDAAN,
 
20
 
 a family of sta-
tistical procedures for analysis of data from complex sample surveys.
The direct method was used to adjust prevalence estimates for age
in order to standardize comparisons.
 
21
 
 The reference population was
the 1980 U.S. population. Multivariate analyses were performed with
logistic regression. The weighted odds ratios and 95 percent confi-
dence intervals were based on standard errors incorporating the
complex sample design.
 
R
 
ESULTS
 
Relation of Age, Sex, Race, and Ethnicity to Levels of 
Tetanus Antibodies 
 
Overall, 69.7 percent of the U.S. population six years
of age and older had protective levels of tetanus anti-
bodies (age-adjusted value, 70.3 percent) (Fig. 1). The
prevalence of immunity varied according to age, re-
maining above 80 percent for persons 6 through 39
years of age. Beginning at the age of 40, the prevalence
of immunity dropped sharply with increasing age, until
it reached 27.8 percent in the group of respondents
who were 70 or more years old (Fig. 1). A similar pat-
tern was seen among non-Hispanic whites and non-
Hispanic blacks, whereas for Mexican Americans the
prevalence of immunity began to decrease earlier.
For all racial and ethnic groups, men had significant-
ly higher age-adjusted rates of immunity than women.
The large differences in the rates between men and
women 40 years of age and older accounted for most of
this gap.
 
Correlates of Immunity
 
Because of the strong effect of age on the prevalence
of immunity to tetanus, the analyses in Table 1 were
adjusted for age in order to standardize the compari-
son between racial and ethnic groups. The unadjusted
prevalence is presented for comparison. Non-Hispanic
whites had the highest rate of immunity (72.7 percent),
followed by non-Hispanic blacks (68.1 percent) and
then by Mexican Americans (57.9 percent).
Poverty, defined as a poverty-index ratio of less than
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1, was associated with a lower rate of immunity, except
among non-Hispanic blacks. Birth outside the United
States and lower educational status among persons at
least 17 years of age were associated with lower rates
of immunity. No consistent association with urban or
rural residence was noted.
Among subjects who were at least 20 years of age,
men with a history of military service had a higher rate
of immunity to tetanus than men who were not veterans
(Fig. 2), and the difference between groups increased
with age. Women without a history of military service
had lower levels of protection than either male veterans
or male nonveterans.
 
Multivariate Analysis
 
Logistic-regression analysis was conducted to deter-
mine whether any variables were independent predic-
tors of protective levels of tetanus antibodies. After
adjustment for age, the following were all significant
predictors of immunity to tetanus: male sex (odds ratio,
2.2; 95 percent confidence interval, 1.9 to 2.5), non-
Hispanic white race (odds ratio, 1.5; 95 percent confi-
dence interval, 1.2 to 1.7), birth in the United States or
Canada (odds ratio, 3.4; 95 percent confidence interval,
2.5 to 4.5), military service (odds ratio, 3.5; 95 percent
confidence interval, 2.8 to 4.6), and some college edu-
cation (odds ratio, 1.5; 95 percent confidence interval,
1.3 to 1.8).
 
Prevalence of Immunity among Children 6 to 16 Years
of Age
 
Of the children 6 to 16 years of age, 82.2 percent had
protective levels of tetanus antibodies. The prevalence
of immunity to tetanus varied little according to racial
or ethnic group (non-Hispanic whites, 81.8 percent;
non-Hispanic blacks, 83.0 percent; Mexican Ameri-
cans, 85.2 percent).
The rate of immunity to tetanus was approximately
96 percent in six-year-olds and 90 percent in children
seven to nine years of age. For children 10 to 16 years
of age, the rate dropped to 80 percent. There was little
difference in this pattern among the three racial and
ethnic groups.
The prevalence of immunity decreased as the length
of time since the last tetanus immunization increased.
Among children 6 to 16 years old who reported having
been immunized less than one year before the inter-
view, 94.9 percent were immune. This value dropped to
 
Figure 1. Age-Specific Prevalence of Immunity to Tetanus According to Racial and Ethnic Group in the NHANES III Popu-
lation, 1988 to 1991.
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85.6 percent among those reporting that they had last
been immunized 1 to 5 years before the interview, to
72.1 percent among those immunized 6 to 10 years be-
fore the interview, and to 69.4 percent among those im-
munized 11 or more years before the interview.
None of the risk factors examined in this age group
(access to health care, poverty status, or educational
level of the head of the household) were associated with
the level of immunity to tetanus.
 
Immunity to Tetanus in Relation to Disease Incidence
 
Although the prevalence of immunity to tetanus de-
clined rapidly starting at the age of 40 years, most of
the 107 cases of tetanus and 20 deaths from tetanus re-
ported in 1989 and 1990 occurred in persons who were
60 years of age or older (Fig. 3).
 
D
 
ISCUSSION
 
We used data from NHANES III to identify low rates
of immunity to tetanus among the elderly, especially
among older women. A history of military service was
associated with substantially higher rates of immunity
to tetanus, although the rates among male nonveterans
were higher than those among female nonveterans.
This may reflect the higher accident rate among men,
since accidents increase the probability of receiving a
tetanus booster.
The number of cases of tetanus has remained rel-
atively stable, with 48 to 64 cases reported annually
since 1986.
 
19,22
 
 For the period from 1979 to 1984, the
completeness of tetanus case reporting to the national
surveillance system at the CDC was estimated to be be-
tween 22 percent and 46 percent. Thus, the total num-
ber of cases of tetanus in the United States may be two
to four times higher than the number of cases reported
to the CDC.
 
23
 
Most cases of tetanus in the United States occur
among adults who are unvaccinated or whose history of
vaccination is unknown.
 
19
 
 Earlier exposure to tetanus
toxoid through the completion of a primary series of
vaccinations may allow an anamnestic response on ex-
posure to tetanus despite the presence of low circulat-
ing antibody levels. Other potential factors contribut-
ing to the low rate of morbidity include appropriate
postexposure wound prophylaxis and decreased expo-
sure to tetanus spores.
Although the rate of immunity to tetanus in school-
children in general exceeded 80 percent, this rate is
 
*Adjusted for age according to the 1980 U.S. Census.
†Participants with missing data were not included in the analysis.
‡This analysis was limited to participants at least 17 years of age.
 
Table 1. Unadjusted and Age-Adjusted Correlates of Immunity to Tetanus among NHANES III Participants Six Years of
Age or Older, 1989 to 1991.
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
 
3260)
 
percent (95 percent confidence interval)
 
Unadjusted
 
10,618 69.7 (67.9–71.5) 71.0 (69.3–72.7) 71.0 (68.5–73.5) 63.7 (61.2–66.2)
 
Age-adjusted
 
10,618 70.3 (68.8–71.8) 72.7 (71.4–74.0) 68.1 (66.4–69.8) 57.9 (55.7–60.1)
Sex
Male
Female
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
 
1
 

 
1
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much lower than the reported rate of 96 to 97 percent
for the completion of three or more DTP immunizations
at school entry.
 
2
 
 Several factors may contribute to this
discrepancy. Over 99 percent of the school-age respond-
ents in NHANES III attended school and therefore were
subject to immunization laws. Less than 5 percent of
parents requested that their children be exempted from
these laws for religious or philosophical reasons (CDC:
unpublished data). Therefore, exemption was not a ma-
jor contributor to the lack of serologic immunity in the
United States.
It is also possible that the rate of tetanus-vaccination
coverage reported at school entry is an overestimate.
However, this seems unlikely, since nearly all states rely
on provider-reported immunization histories, which list
the dates of each vaccination. Primary vaccine failure
seems unlikely because tetanus toxoid is a very effective
antigen, with a high level of response after only two im-
munizations. Ruben et al.
 
24
 
 found that 98.7 percent of
children six months to two years of age who received
two doses of DTP two months apart had protective lev-
els of tetanus antibody. Myers et al. examined serocon-
version rates in 48 patients 6 to 58 years of age. After
the second immunization with tetanus toxoid, 100 per-
cent had protective levels.
 
25
 
Waning immunity after immunizations may account
for the lack of protective antibody levels in some of the
NHANES III respondents. Waning immunity is related
to the antibody titer and the number of immunizations
received. At least three vaccinations against tetanus
are required to ensure adequate, long-lasting immuni-
ty.
 
26
 
 In one group of subjects 13 to 20 years of age who
had been vaccinated 7 to 13 years earlier, the rate of
immunity varied according to the number of immuni-
zations received. Ninety-one percent of those who had
received three injections were immune, 65 percent
of those who had received two injections were im-
mune, and 50 percent of those who had received one
injection were immune.
 
27
 
 In a randomly selected sam-
ple of Danes 25 to 30 years of age who had received a
primary series of three immunizations against tetanus
but no booster vaccinations, 90 percent of those vacci-
nated less than 20 years earlier still had protective lev-
els, and 72 percent of those vaccinated more than 25
years earlier were still protected.
 
28
 
Given the results of the Danish study, children who
receive three or more tetanus immunizations should
not lose their protective levels for many years. The tet-
anus toxoid used in Denmark, however, is approximate-
ly 40 percent more potent than that used in the United
States. Thus, in the United States, the three immuniza-
tions required by law for school entry may not provide
lasting immunity. The recommendation of the Advisory
Committee on Immunization Practices
 
29
 
 and the Amer-
ican Academy of Pediatrics
 
30
 
 for five immunizations by
the age of six may be a more appropriate standard. In
addition, a booster at adolescence is needed to ensure
long-lasting immunity.
The absence of an association of immunity to tetanus
with known risk factors (such as lower socioeconomic
status, minority status, and birth outside the United
States) among the group of children 6 to 16 years old
is not surprising, given that school-entry requirements
for vaccination apply to nearly all. The risk factors
identified in children tend to apply only to the pre-
school-age group.
 
2,31
 
The lack of protective immunity among older adults
has been noted in the United States for the past several
decades.
 
3,4
 
 In 1983, Weiss et al.
 
4
 
 reported protective
levels of tetanus antibodies in only 54 percent of per-
sons frequenting a senior-citizen center (mean age, 69
years) and 29 percent of patients in a convalescent hos-
pital (mean age, 82 years). Military service has previ-
ously been associated with higher rates of protection
against tetanus.
 
4
 
 Our findings corroborate the fact that
very little has changed in the past 10 to 15 years.
The current recommendations are to give tetanus
booster immunizations every 10 years to all adults.
 
29,30
 
Some have argued that after the first booster dose,
booster doses are needed only every 20 years to main-
tain immunity.
 
32
 
 Balestra and Littenberg
 
33
 
 have con-
tended that a single booster dose at the age of 65 years
to those who completed the primary series of immuni-
zations in childhood would be a cost-effective strategy
to decrease tetanus in adults. However, administering a
primary series of tetanus toxoid (given with diphtheria
toxoid) to elderly persons who have never been vacci-
nated may offer the best means of rapidly decreasing
the tetanus burden in the United States.
 
R
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